Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has announced the pricing of its initial public offering of 23,529,412 shares of its common stock, at a public offering price of US$21 per share. In addition, Caris has granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol “CAI.” The offering is expected to close on June 20, 2025, subject to customary closing conditions.
Latham & Watkins LLP is advising Caris Life Sciences in the offering with a corporate team led by New York partners Nathan Ajiashvili and Alison Haggerty, and Austin partner Samer Zabaneh, with associates Sandy Kugbei, Jie Lin Nai, Akina Newbraugh, and Radley Gillis.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
